Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.
Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
06 Feb 2023Pain, discomfort persist in JIA patients despite medication use
Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.
Pain, discomfort persist in JIA patients despite medication use
18 Jan 2023Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.
Can RA patients taper MTX from targeted therapy?
18 Jan 2023CVD, mood disorders up risk of dementia in RA patients
Among patients with rheumatoid arthritis (RA), those with clinically active RA, cardiovascular or cerebrovascular disease (CVD), hypertension, depression, and anxiety are at greater risk of dementia, reveals a study. Among CVD events, ischaemic stroke and heart failure are significantly associated with an increased dementia risk.
CVD, mood disorders up risk of dementia in RA patients
17 Jan 2023Etanercept biosimilar demonstrates long-term safety, efficacy in rheumatoid arthritis
YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.